Arcus Biosciences’ Post

Just wrapped an inspiring week at JP Morgan Healthcare Conference! Our key takeaways: #JPMHC24 #HealthcareInnovation #PatientCentricCare #FutureOfHealthcare

At the recent AGS Health Partner Summit, our CEO, Patrice Wolfe, provided insights gained from the 42nd annual JP Morgan Healthcare Conference, highlighting five pivotal trends shaping the industry's trajectory. To learn more, read our recent blog diving into the current top priorities of leadership at large health systems and other healthcare organizations. https://hubs.la/Q02tCxMh0

42nd Annual J.P. Morgan Healthcare Conference has come and gone—but despite the packed rooms, there was a major elephant in the room that no one seemed to acknowledge. Not all companies can be winners. In our latest blog post, we dive deep into the industry's pulse to uncover crucial takeaways that were left unspoken. More than 42% of shutdown start-ups launched a product that showed little to no differentiation compared to existing commercial products—we’d say there is a serious problem on our hands. Ready to unlock the secrets that didn't make it to the conference floor? Learn more: https://loom.ly/k0PYh5U

How to Prepare for the J.P. Morgan Healthcare Conference ✔️ Make a plan to divide and conquer ✔️ Refresh your deck ✔️ Time good news to coincide with the event ✔️ Book a meeting room for a full day of meetings https://hubs.la/Q02cPtLp0

In this month's blog, I explore the top themes and trends from this year's JP Morgan Healthcare Conference. If you missed it, you can catch up on the highlights here: https://lnkd.in/e7WgcZa5. Did you attend? Let us know your thoughts and takeaways in the comments below! Lee Kester Molly White Jones Kester Search Group, LLC ® #JPmorganhealthcare #healthcaretrends

A strategy that follows the needs of today.

So, I am back from JPM Healthcare conference in SanFran.  It was a crazy week and a great experience. My 5 takeaways: (1) It is THE place to be for Pharma / Biotech partnering (2) Specifically for publicly traded organisations, presenting your company at the conference is a must to enforce your relevancy (3) The action is outside of the actual conference - majority of people don’t attend the conference but rather meet for business development, investment, or company analysis (4) Getting invited and attending the right evening receptions is even more critical than formal meetings. I had five receptions in one evening - could only make 3 of the 5 but they were worth it. (5) And MOST importantly, wear comfortable walking shoes and bring a good umbrella as you are moving between all the various hotels in central SanFran as you race to get to your next meeting. As mentioned previously, our BenevolentAI's Chairman & acting CEO, Francois Nader presented at the conference and did a fabulous job. He even mentioned my name as the Chief Revenue Officer in spearheading our way forward - quite an honour! The link to the recording is below.  In my PoV it is worth 20 minutes of your time. However, if you don't have time here is my recap: We are at the intersection of Pharma & Tech and  a pioneer & leader in AI-augmented drug discovery, enabled by the Benevolent Platform. We stand above our competition of AI in drug discovery as not only have we been doing it for 10 years, but we are also one of the rare platforms that has validated our approach via three ways : (1) Successful collaborations with AstraZeneca with TargetID and most recently Merck Healthcare KGaA with Chemistry. For AstraZeneca the products are in the pipeline and they're real. (2) We leveraged our indication expansion capabilities to identify Eli Lilly and Company's rheumatoid arthritis drug Olumiant (baricitinib) as a potential treatment for COVID-19, which received an emergency use authorisation from the US FDA in 2020; full approval in May 2022. (3) Our platform has generated 5 wholly owned products in a pipeline that looks like a traditional Biotech. Our lead asset BEN-8744 is an oral PDE10 inhibitor in Phase I which is a potential first-in-class option for ulcerative colitis. Our Business model offers multiple routes for value creation. In addition to our high potential R&D pipeline and our leading E2E Drug Discovery solutions mentioned above, we have a new expansion opportunity through suite of Knowledge Exploration tools that acting as a co-pilot for scientists, leverages bio-specific natural language processing (NLP) and large language models (LLM) to surface data, perform analysis, and give scientific recommendations to drive new insights and increase productivity. So, as you can see from above, this is a very exciting time for BenevolentAI and I am thrilled to be part of the journey! #JPM2024 #drugdiscovery #aidrugdiscovery #generativeai #researchanddevelopment

Have you register yet for this year's #NCQASummit? Don't miss out on key insights from healthcare industry thought leaders, thought provoking breakout sessions, and powerful networking opportunities with like minded healthcare professionals actively advancing healthcare forward. Learn More: https://bit.ly/43LyGt3

Looking forward to meeting #industryexecutives and #investors from around the world at the #jpm2024 in San Francisco. If you're in the area, it would be great to catch up and network. #Vamstar is transforming how the #buyers and #suppliers in the healthcare market operates by focusing on its essential components: #data, #tradinginfrastructure, #technology, #people, and #processes. We're revolutionising the industry's commerce in #medicaldevices, #medicaltechnology , #biosimilars, and #pharmaceuticals by using #AI to seamlessly integrate suppliers' #commercial teams with buyers' #sourcingandprocurement teams, along with its related #processes. The #healthcare #ecosystem is in a critical condition, and we are building solutions that can improve #margins for everyone involved and reduce risks across the entire #supplychain.

Follow here for three part series on insights an takeaways from JP Morgan Healthcare conference. What are the big forces of change impacting the industry? What does that mean fro marketers? And how will it impact launches in the coming year?